Diabetic neuropathy is a nerve destructive disorder associated with diabetes mellitus. It is defined by the presence of proteinuria. It is a form of chronic kidney disease which occurs when the kidney is exposed to persistent hyperglycemia. It is damage caused to the nerve due to diabetes that often leads to pain & numbness in feet or lower legs. The pain can be experienced in other parts of the body for instance wrist, hips, and back depending upon the effect of neuropathy. It affects about 20-40% of patients with diabetes mellitus.
According to the study, “Global diabetic neuropathy Market Size study, by Disorder Type (autonomic Neuropathy, peripheral neuropathy, proximal neuropathy, and focal Neuropathy) Treatment (drugs, physiotherapy, radiotherapy, and others) Distribution Channel (clinics, hospitals and pharmacy) and Regional Forecasts 2018-2025” the key companies operating in the global diabetic neuropathy market areMEDA Pharma GmbH & Co. KG, Cephalon, Inc., Pfizer Inc., Eli Lilly, and Company, Janssen Pharmaceuticals, Inc., Abbott Laboratories, Daiichi Sankyo Company Limited, ACTAVIS, NeuroMetrix, Inc., Novartis AG, Johnson & Johnson Services, Inc., Lupin Limited, GlaxoSmithKline. The key vendors are progressively focusing on the development of disease-modifying drugs to treat diabetic neuropathy owing to its growing prevalence. Vendors are also focusing on the introduction of injectable gene therapy aimed at enduring pain relief associated with diabetic peripheral neuropathy.
Based on disorder type, the global diabetic neuropathy market is segmented into autonomic neuropathy, peripheral neuropathy, focal neuropathy, and proximal neuropathy. The autonomic neuropathy segment affects body function such as blood pressure, heart rate, digestion, and perspiration. Peripheral neuropathy affects the legs and feet. Focal neuropathy affects the nerves, foot, wrist, and thigh. Proximal neuropathy affects hips, thighs, legs, and buttocks. Based on treatment type, the market is segmented into physiotherapy, drugs, radiotherapy, and others. Drugs segment is further sub-segmented into antidepressant (Selective Nor-epinephrine Reuptake Inhibitors (SNRIs), Tricyclic Anti-depressants (TCAs), Selective Serotonin Reuptake Inhibitors (SSRIs)), analgesics (opioids (morphine and others), topical (capsaicin and others) and non-steroidal anti-inflammatory drugs (NSAIDs)) and anticonvulsants (topiramate, pregabalin, gabapentin, and others). Additionally, radiotherapy is further sub-segmented into TENS and others. In addition, based on the distribution channel, the market is segmented into retail pharmacies, hospitals, online pharmacy and clinics.
The global diabetic neuropathy market is driven by a rise in the prevalence of diabetes, followed by a change in lifestyle habits, rise in urbanization, growth in awareness regarding diagnosis & treatment of diabetes, approval of new drugs, rise in demand for the development of better neuropathy drugs, the presence of a strong drug pipeline and change in genetic composition. However, the high cost of diabetic drugs, lack of absolute treatment, side effects with the diabetic neuropathy treatment and lack of awareness among the patients may impact the market. Moreover, growth in the prevalence of obesity & numerous cardiovascular diseases is a key opportunity for the market. Furthermore, favorable reimbursement scenario and new therapeutics for the treatment of neuropathy is a major trend for the market.
Based on geography, the North-American region holds the leading position in diabetic neuropathy market owing to improvement in healthcare infrastructure, an increase in the prevalence of diabetes and a rise in research and development (R&D) activities for drug discovery in the region. Whereas, the Asian-Pacific and European regions are expected to witness higher growth rate due to the increase in aging population and improvement in healthcare services in rural areas over the forecast period. In upcoming years, it is estimated that the future of the market will be bright on account of growth in the development of novel biologics to treat diabetic neuropathy and the launch of a new medication to manage the symptoms of chronic diabetic neuropathy during the forecast period. It is expected that the market will be reached at the US $5.8 billion by 2025.
To Know More, Click On The Link Below:-Global Diabetic Neuropathy Market Analysis
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment